Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals
NCT01029223 · Bayside Health · PHASE4 · withdrawn · last registry update 2011-11-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Bayside Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCN4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2012-10-26Results posted on the registry: Sanofi, Dronedarone + Placebo (for Dronedarone) (NCT01151137)
- 2012-10-26Also stopped (terminated): Sanofi, Dronedarone + Placebo (for Dronedarone) (NCT01151137)
- 2012-08-14Results posted on the registry: Boehringer Ingelheim, Dabigatran etexilate plus dronedarone + Dabigatran etexilate (NCT01306162)
- 2012-08-06Phase 3 first posted: Policlinico Casilino ASL RMB, Ivabradine + Beta blocker (NCT01657136)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision